# BioXcel (BTAI) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/BTAI
## Company Profile
- Ticker: BTAI
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology, CNS
## Stock Data
- Close: 0.0739 USD
- Market cap: 36744349.949999996 USD
- Last updated: 2026-09-04
## Business Overview
BioXcel Therapeutics is a neuroscience and immuno-oncology company focused on using artificial intelligence to identify therapeutic candidates. Its story combines data-driven discovery with development-stage biotech execution.
## Why The Stock Is Moving

As of Sep 4, 2026, BTAI closed down 37.1% at $0.0739. No new same-company headline was identified in the current news window.

## Geographic Base

BioXcel is headquartered in the United States and listed on NASDAQ. It sits in neuroscience and platform biotechnology.

## Business Model

The company depends on clinical progress, platform validation, and the ability to turn AI-enabled discovery into real therapeutic value. Investors watch data, safety, and pipeline prioritization.

## Landscape Position

BioXcel occupies a platform-heavy neuroscience niche within biotech. The stock is driven by whether its AI-assisted approach can support a viable pipeline.

## Future Catalysts

- BioXcel’s catalysts are IGALMI and the neuroscience pipeline, plus any strategic update that clarifies the company’s commercial path. The market will care about whether the product base can stabilize.

## Recent News
- 2026-08-28 10:00 EST — [BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-enters-into-asset-sale-agreement-with-teva-pharmaceuticals-f7d2be81) — Source: BioXcel
- 2026-05-28 11:00 EST — [BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-presents-new-data-from-serenity-at-home-phase-3-trial-for-agitation-associated-with-bipolar-disorders-or-schizophrenia-at-2026-ascp-annual-meeting) — Source: BioXcel
- 2026-05-15 11:00 EST — [BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-provides-business-update-and-reports-first-quarter-2026-financial-results) — Source: BioXcel
- 2026-04-17 11:00 EST — [BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-virtual-event-to-discuss-commercial-launch-plan-based-on-market-opportunity-assessment-for-igalmir-in-the-at-home-setting) — Source: BioXcel
- 2026-04-08 11:00 EST — [BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-enrollment-of-first-patients-in-u-s-department-of-war-funded-study-of-bxcl501-sublingual-dexmedetomidine-for-treatment-of-acute-stress-reactions) — Source: BioXcel